推薦產品
產品名稱
γ-分泌酶抑制剂XXI，化合物E, This g-secretase inhibitor, CAS 209986-17-4, is a cell-permeable, potent, selective, non-transition-state analog inhibitor of γ-secretase and Notch processing. Lowers Aβ levels in APP transgenic mice
化驗
≥95% (HPLC)
形狀
solid
製造商／商標名
Calbiochem®
儲存條件
OK to freeze
protect from light
顏色
white
溶解度
DMSO: 10 mg/mL
運輸包裝
ambient
儲存溫度
2-8°C
SMILES 字串
Fc1cc(cc(c1)CC(=O)N[C@@H](C)C(=O)NC2N=C(c4c(cccc4)N(C2=O)C)c3ccccc3)F
InChI
1S/C27H24F2N4O3/c1-16(30-23(34)14-17-12-19(28)15-20(29)13-17)26(35)32-25-27(36)33(2)22-11-7-6-10-21(22)24(31-25)18-8-4-3-5-9-18/h3-13,15-16,25H,14H2,1-2H3,(H,30,34)(H,32,35)/t16-,25?/m0/s1
InChI 密鑰
JNGZXGGOCLZBFB-YPHZTSLFSA-N
一般說明
γ-分泌酶和Notch加工的一种细胞可渗透的、有效的、选择性的、拟肽的、非过渡态类似物抑制剂（在过表达野生型βAPP的CHO细胞中，Aβ40的IC50为300 pM；在用βAPP695和mNotchΔE(M1727V)稳定转染的HEK293细胞中，Aβ40、Aβ42、NICD的IC50分别为240 pM、370 pM、320 pM；在SPA4CT稳定转染的SH-SY5Y细胞中，Aβ40和Aβ42的IC50为100 pM）在几个APP转基因小鼠模型中降低Aβ水平。据报道，与早老素结合并抑制跨膜蛋白底物的蛋白水解裂解，包括APLP1和APLP2、CD44、ErbB4、E-钙粘蛋白、低密度脂蛋白受体相关蛋白、Notch配体和p75NTR。在更高浓度（200-400 µM）下，对早老酶活性的影响很弱。
生化／生理作用
主要靶标
过表达野生型bAPP的CHO细胞中的γ-分泌酶和Notch加工Ab40
过表达野生型bAPP的CHO细胞中的γ-分泌酶和Notch加工Ab40
产物不与ATP竞争。
可逆：否
细胞可渗透性：是
靶标IC50：在过表达野生型βAPP的CHO细胞中，对于Aβ40，为300 pM；在用βAPP695和mNotchΔE(M1727V)稳定转染的HEK293细胞中，对于Aβ40、Aβ42、NICD，分别为240 pM、370 pM、320 pM；对于Aβ40为100 pM
包裝
用惰性气体包装
警告
毒性：标准处理（A）
重構
复溶后，等分并冷冻保存（-20°C）。贮备溶液在-20°C下可稳定保存至多6个月。
其他說明
Milano, J., et al. 2004.Toxicol.Sci.82, 341.
Jung, K.M., et al. 2003.J. Biol. Chem.278, 42161.
Murakami, D., et al. 2003.Oncogene22, 1511.
Campbell, W.A., et al. 2003.J. Neurochem.85, 1563.
Berechid, B.E., et al., 2002.J. Biol. Chem.277, 8154.
Lee, H.J., et al. 2002.J. Biol. Chem.277, 6318.
May, P., et al. 2002.J. Biol. Chem.277, 18736.
Scheinfeld, M.H., et al. 2002.J. Biol. Chem.277, 44195.
Ni, C. Y., et al. 2001.Science294, 2179.
Beher, D., et al. 2001.J. Biol. Chem.276, 45394.
Doerfler, P., et al. 2001.Proc.Natl.Acad.Sci. USA98, 9312.
Seiffert, D., et al. 2000.J. Biol. Chem.275, 34086.
Jung, K.M., et al. 2003.J. Biol. Chem.278, 42161.
Murakami, D., et al. 2003.Oncogene22, 1511.
Campbell, W.A., et al. 2003.J. Neurochem.85, 1563.
Berechid, B.E., et al., 2002.J. Biol. Chem.277, 8154.
Lee, H.J., et al. 2002.J. Biol. Chem.277, 6318.
May, P., et al. 2002.J. Biol. Chem.277, 18736.
Scheinfeld, M.H., et al. 2002.J. Biol. Chem.277, 44195.
Ni, C. Y., et al. 2001.Science294, 2179.
Beher, D., et al. 2001.J. Biol. Chem.276, 45394.
Doerfler, P., et al. 2001.Proc.Natl.Acad.Sci. USA98, 9312.
Seiffert, D., et al. 2000.J. Biol. Chem.275, 34086.
法律資訊
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
儲存類別代碼
11 - Combustible Solids
水污染物質分類（WGK）
WGK 3
閃點（°F）
Not applicable
閃點（°C）
Not applicable
分析證明 (COA)
輸入產品批次/批號來搜索 分析證明 (COA)。在產品’s標籤上找到批次和批號，寫有 ‘Lot’或‘Batch’.。
客戶也查看了
Claire E McGhee et al.
ACS central science, 7(11), 1809-1820 (2021-11-30)
Lithium has been a drug for bipolar disorders (BD) for over 70 years; however, its usage has been limited by its narrow therapeutic window (between 0.6 and 1.2 mM). Understanding the cellular distribution of lithium ions (Li+) in patient cells
Kenichi Makino et al.
Journal for immunotherapy of cancer, 10(1) (2022-02-02)
Dendritic cells (DCs) play critical roles in regulating the innate and adaptive immune responses, and have long been a major focus of cancer immunotherapy. Accumulating evidence suggests that conventional type 1 DCs (cDC1s) excel in cross-presentation of exogenous antigens on
Christine E Eyler et al.
Genome biology, 21(1), 174-174 (2020-07-17)
Tumors can evolve and adapt to therapeutic pressure by acquiring genetic and epigenetic alterations that may be transient or stable. A precise understanding of how such events contribute to intratumoral heterogeneity, dynamic subpopulations, and overall tumor fitness will require experimental
Louise Thiry et al.
ASN neuro, 14, 17590914211073381-17590914211073381 (2022-01-14)
Human induced pluripotent stem cells (hiPSCs) derived from healthy and diseased individuals can give rise to many cell types, facilitating the study of mechanisms of development, human disease modeling, and early drug target validation. In this context, experimental model systems
Deli Hong et al.
Cancer research, 82(2), 248-263 (2021-11-24)
Neuroendocrine to nonneuroendocrine plasticity supports small cell lung cancer (SCLC) tumorigenesis and promotes immunogenicity. Approximately 20% to 25% of SCLCs harbor loss-of-function (LOF) NOTCH mutations. Previous studies demonstrated that NOTCH functions as a SCLC tumor suppressor, but can also drive
Active Filters
我們的科學家團隊在所有研究領域都有豐富的經驗，包括生命科學、材料科學、化學合成、色譜、分析等.
聯絡技術服務
